Literature DB >> 34009515

Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling.

Zeyu Xing1, Menglu Zhang1, Xin Wang1, Jiaqi Liu1, Gang Liu1, Kexin Feng1, Xiang Wang2.   

Abstract

Breast cancer is a frequent cancer among women. The current study investigated the biological functions of Nek2 in breast cancer and its possible mechanism. The mRNA expression of Nek2 in breast epithelial cells and eight breast cancer cell lines was detected by qRT-PCR. Silencing Nek2 was transfected into MDA-MB-231 and MCF7 cells to examine its roles in the viability, migration, invasion, cell colony, apoptosis and cell cycle of the breast cancer cells by performing CCK-8, wound scratch, Transwell, clone formation and flow cytometry assays, respectively. The expressions of related genes were detected using qRT-PCR and Western blot. MAPK pathway agonist IGF (insulin-like growth factor-1) was added into MDA-MB-231 and MCF7 cells and then cell viability was examined. Nek2 expression was frequently up-regulated in breast cancer cell lines, and silencing Nek2 significantly inhibited the viability, cell migration, invasion and clone formation, promoted cell apoptosis of MDA-MB-231 and MCF7 cells, and arrested cell cycle in G0/G1 phase. Furthermore, knocking down Nek2 decreased the mRNA and protein expressions of Bcl-2, CyclinB1 and CyclinD1, and increased Bax and p27 expressions. Moreover, knocking down Nek2 inhibited the phosphorylation of ERK and p38, and almost completely reversed the expression of p-ERK increased by IGF, but Nek2 knockdown had no obvious effect on p-p38. The inhibitory effect of Nek2 silencing on the cell viability was mainly realized by the inhibition of ERK/MAPK signaling. Nek2 plays an important role in the regulation of the progression of breast cancer in vitro probably through regulating the ERK/MAPK signaling.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Biological function; Breast cancer; ERK/MAPK signaling; Nek2

Mesh:

Substances:

Year:  2021        PMID: 34009515     DOI: 10.1007/s10735-021-09979-9

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  41 in total

Review 1.  Ductal carcinoma in situ of breast: update 2019.

Authors:  Sunil S Badve; Yesim Gökmen-Polar
Journal:  Pathology       Date:  2019-08-28       Impact factor: 5.306

Review 2.  Breast Cancer: Current Perspectives on the Disease Status.

Authors:  Mohammad Fahad Ullah
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 3.  Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.

Authors:  Scott T Eblen
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

4.  Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells.

Authors:  P Cappello; H Blaser; C Gorrini; D C C Lin; A J Elia; A Wakeham; S Haider; P C Boutros; J M Mason; N A Miller; B Youngson; S J Done; T W Mak
Journal:  Oncogene       Date:  2013-05-27       Impact factor: 9.867

5.  Type of breast cancer diagnosis, screening, and survival.

Authors:  Carla Cedolini; Serena Bertozzi; Ambrogio P Londero; Sergio Bernardi; Luca Seriau; Serena Concina; Federico Cattin; Andrea Risaliti
Journal:  Clin Breast Cancer       Date:  2014-02-20       Impact factor: 3.225

6.  Label-Free Quantitative Proteomics in a Methylmalonyl-CoA Mutase-Silenced Neuroblastoma Cell Line.

Authors:  Michele Costanzo; Armando Cevenini; Emanuela Marchese; Esther Imperlini; Maddalena Raia; Luigi Del Vecchio; Marianna Caterino; Margherita Ruoppolo
Journal:  Int J Mol Sci       Date:  2018-11-13       Impact factor: 5.923

7.  NIMA related kinase 2 promotes gastric cancer cell proliferation via ERK/MAPK signaling.

Authors:  Wei-Dong Fan; Tao Chen; Peng-Jun Liu
Journal:  World J Gastroenterol       Date:  2019-06-21       Impact factor: 5.742

8.  Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.

Authors:  Ling Deng; Jingyuan Sun; Xiaohui Chen; Li Liu; Dehua Wu
Journal:  J Exp Clin Cancer Res       Date:  2019-07-18

9.  Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol.

Authors:  Ilija Androic; Andrea Krämer; Ruilan Yan; Franz Rödel; Regine Gätje; Manfred Kaufmann; Klaus Strebhardt; Juping Yuan
Journal:  BMC Cancer       Date:  2008-12-29       Impact factor: 4.430

Review 10.  Drug Combinations in Breast Cancer Therapy.

Authors:  Funmilola A Fisusi; Emmanuel O Akala
Journal:  Pharm Nanotechnol       Date:  2019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.